SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos (CWD) is trending following news of its initial purchase of Chainlink tokens as part of a new digital asset treasury strategy, sparking excitement similar to the recent surge in $OCTO. The community is actively discussing the potential for continued upward momentum, drawing comparisons to other low-float stocks and highlighting the absence of options trading as a factor influencing the stock's behavior.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending due to a recently announced $17.4B deal with Microsoft for AI infrastructure, leading to comparisons with other AI infrastructure plays like CRWV. Community members are speculating about future deals with other major tech companies and the potential for a short squeeze. Some investors believe this is just the beginning for NBIS as it gains recognition as a key player in the AI cloud space.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending due to a recent public offering of 40 million shares at $5.00, sparking concerns about dilution among investors, while others view the $200M capital raise as a bullish move for strategic growth and potential acquisitions. The community is actively debating the implications of the offering, with some expressing frustration and others seeing it as a necessary step for the company's expansion in the drone technology sector.

Cleancore Solutions, Inc. engages in the development and production of cleaning products that produce pure aqueous ozone for professional, industrial, or home use. Its products include fill station 1.0. fill station 3.0, power caddy, minicaddy, ice treatment machine, O3 cleanpak, commercial laundry, and residential laundry. The company was founded on August 23, 2022 and is headquartered in Omaha, NE.

CleanCore Solutions Inc. - Ordinary Shares - Class B

Cleancore Solutions Inc.

CleanCore Solutions (ZONE) is trending due to its strategic move into the Dogecoin space, including the establishment of a Dogecoin treasury. Community discussions revolve around the potential for a significant price surge, drawing comparisons to other crypto-related stocks that have experienced rapid gains. Some investors express optimism about the company's leadership and future prospects, while others caution against FOMO and highlight the stock's volatility.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors eagerly await earnings, with anticipation building around potential revenue growth and updates on the company's crypto-focused strategy. The community is split, with some expecting a positive surprise and others bracing for volatility or another share offering. Discussions also revolve around Ryan Cohen's leadership and the potential for a short squeeze.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Big Tree Cloud Holdings Ltd. is a holding company, which engages in providing personal care products through its subsidiaries. The company was founded by Wenquan Zhu in 2020 and is headquartered in Shenzhen, China.

Big Tree Cloud Holdings Ltd.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, Ketjen, and All Other. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The All Other segment refers only to the FCS business that did not fit into any of the company’s core businesses. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates potential ETF approval and discusses the recent accumulation of DOGE by institutions, including CleanCore's treasury initiative. Bullish sentiment is fueled by technical indicators and the possibility of increased adoption, while some traders are wary of potential pullbacks. The conversation also includes comparisons to other meme coins and the potential impact of Elon Musk's X platform on Dogecoin's utility.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as the top meme coin on Bitcoin, with the community emphasizing its fair launch, decentralization, and strong ties to the Bitcoin network. Discussions highlight its potential to onboard new users to Bitcoin and its unique position compared to meme coins on other chains. A recent expansion of C2 Blockchain's corporate treasury into $DOG.X may also be contributing to the increased attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Wave Life Sciences (WVE) tumbled over 19% on Wednesday after the company announced that its WVE-006 led to RNA editing in all participants treated in a trial evaluating the therapy as a treatment for alpha-1-antitrypsin deficiency (AATD).AATD is an inherited genetic disorder that reduces the production of the AAT protein, which is crucial for protecting the lungs and liver. It is caused by a genetic mutation, and WVE-006 is designed to address the manifestations of AATD by correcting the mutation.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-ongoing">announced</a> on Wednesday that WVE-006 resulted in RNA editing in all treated participants, with durable production of serum AAT at levels associated with a lower risk of liver and lung disease following repeat 200 mg doses.Despite the impressive first demonstration of a dynamic acute phase response post-RNA editing in alpha-1-antitrypsin deficiency, Wave Life's stock performance suggests the Street expected a greater increase in AAT protein, Leerink said. Leerink raised its price target on Wave Life Sciences to $26 from $24 and kept an ‘Outperform’ rating on the shares.Leerink further thinks investors should take advantage of this weakness to buy the stock ahead of additional important catalysts, which it remains optimistic investors will appreciate despite today's confusion.H.C. Wainwright analyst Andrew Fein, meanwhile, said Wave’s stock decline despite the “encouraging” data was an “overreaction.” The analyst stated that these results strengthen the firm's conviction that WVE-006 can deliver both lung and liver benefits, and the firm believes the current data, excluding the 400 mg multiple ascending dose data, "still shows an approval endpoint.” The analyst has a ‘Buy’ rating and $22 price target on Wave Life Sciences shares.Data from both the 200 mg and 400 mg single-dose cohorts support a monthly or less frequent subcutaneous dosing regimen, Wave Life Sciences said. Dosing is ongoing in the 400 mg multidose cohort with a monthly dosing regimen, for which Wave expects to deliver data in the first quarter of 2026. Further, all adverse events observed in the study were mild to moderate in intensity, and there were no serious adverse events or discontinuations, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WVE">WVE</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_2_24_05_PM_png_6c95483e4e.webp" alt="WVE's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="623" height="59"><figcaption>WVE's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>GSK has the exclusive global license for WVE-006. Development and commercialization responsibilities will transfer to GSK after Wave completes the study. Wave is eligible for up to $525 million in milestone payments, as well as tiered royalties on net sales, for WVE-006.WVE stock is down 37% this year but up approximately 40% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-reports-near-four-percent-jump-in-us-vehicle-sales-in-august/chwT6RHRd8r">Ford Reports Near 4% Jump In US Vehicle Sales In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why

Wave Life Sciences said Wednesday that its therapy WVE-006 successfully edited RNA in all trial participants, producing lasting levels of a key protein tied to lower risks of liver and lung disease after repeat 200 mg doses.

Equity

BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

Top Analyst Reports for NVIDIA, Chevron & Booking

NVIDIA rides AI and GPU demand, Chevron leverages Hess and Permian output, while Booking gains from strong travel momentum.

GSK Adds Around $5B in a Month: Here's How to Play the Stock

GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.

GSK has secured UK approval for Blujepa (gepotidacin), the first new type of oral antibiotic for urinary tract infections (UTIs) to be cleared in nearly three decades as the drugmaker seeks to grow its infectious disease portfolio.The Medicines and Healthcare products Regulatory Agency (MHRA),&nbsp;the UK’s medicines regulator, has approved Blujepa for use in women and girls aged 12 and older, weighing at least 40 kilos, to treat simple urinary tract infections.UTIs are the most common bacterial infection in women in&nbsp;the UK, with about half of all women in the UK being affected by&nbsp;them. However, patients are at an increasing risk of failure and serious complications, including sepsis and kidney damage, as antibiotic resistance increases.Blujepa acts in a&nbsp;novel way by blocking two bacterial enzymes&nbsp;essential for&nbsp;bacterial replication. It can therefore act on antibiotic-resistant strains such as E. coli.“As the first new type of oral antibiotic to treat uncomplicated UTIs to be approved in nearly three decades, gepotidacin provides a new treatment option for women facing urinary tract infections that can severely impact daily life,” said Julian Beach, Interim Executive Director at the MHRA.&nbsp;The recommended regimen is two tablets twice daily for five days.&nbsp;The approval was based on results from two late-stage Phase 3 studies involving more than 3,100 patients.&nbsp;In those trials, Blujepa was at least as effective as nitrofurantoin, the current standard treatment, even in women with recurrent infections and resistant bacteria, with consistent results.The most common side effects were mild diarrhoea and nausea, affecting more than one in ten patients.On Stocktwits, retail sentiment for GSK was ‘bearish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/GSK">GSK’s stock</a> has risen 22% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Secures UK Approval For First New Oral Antibiotic In 30 Years To Treat Resistant Urinary Tract Infections

The clearance was based on two late-stage Phase 3 trials involving more than 3,100 patients, where Blujepa proved at least as effective as the current standard treatment, even in women with recurrent or drug-resistant infections.

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU

Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.

BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?

Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.



GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GSK News

GSK Glaxosmithkline plc - ADR